Overview

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The primary aim of the study is the comparative effect of zolendronic acid versus denosumab on serum sclerostin levels in postmenopausal women with low bone mass. Secondary aims are their comparative effect on serum dickkopf-1, osteoprotegerin, receptor activator of nuclear factor kappaB ligand (RANKL) and bone turnover markers (procollagen type I N-terminal peptide [PINP] and C-terminal cross-linking telopeptide of type I collagen [CTX]).
Phase:
N/A
Details
Lead Sponsor:
Aristotle University Of Thessaloniki
Collaborators:
251 Hellenic Air Force & VA General Hospital
424 General Military Hospital
Treatments:
Denosumab
Diphosphonates
Zoledronic Acid